Rethinking Dry Eye and Ocular Surface Disease in Glaucoma: Pathophysiology, Diagnosis, and Management.
Ocular surface disease affects up to 60% of patients using glaucoma eye drops.
Rethinking Dry Eye and Ocular Surface Disease in Glaucoma: Pathophysiology, Diagnosis, and Management.
To highlight the overlooked role of ocular surface disease (ocular surface disease) in glaucoma, explore its pathophysiological links to treatment, and propose integrated strategies to improve patient care.
A narrative review of current literature on the relationship between glaucoma therapies and ocular surface health was conducted.
Glaucoma remains the leading cause of irreversible blindness worldwide, with treatment adherence being a critical determinant of long-term outcomes.
Symptoms such as dryness, burning, and blurred vision significantly reduce quality of life and compromise adherence to treatment.
Structured evaluation using questionnaires, slit-lamp examination, and diagnostic tests can facilitate early detection and tailored management.
The ocular surface, long considered secondary in glaucoma care, is central to optimizing both adherence and visual outcomes.
Protecting ocular surface health through preservative-sparing regimens, procedural interventions, and patient-centered strategies is essential.
Reframing ocular surface disease as an integral component of glaucoma management may improve long-term quality of life and enhance treatment success.